Immatics appoints Rainer Kramer as CBO
This article was originally published in Scrip
Immatics Biotechnologies, a biopharmaceutical firm that develops therapeutic cancer vaccines, has appointed Dr Rainer Kramer to the newly created role of chief business officer. The appointment is part of the firm's business strategy aimed at capitalising on its TUMAP-based cancer vaccine pipeline. The firm's lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, have already yielded positive clinical results, says Immatics. Dr Kramer comes to the company from Signature Diagnostics, which specialises in oncology diagnostics, where he served as chief business officer. Before that he was vice-president of business development at Jerini.